Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore
| العنوان: | Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore |
|---|---|
| المؤلفون: | Florence Coussy, Fabien Reyal, Diane De Croze, Thomas Balezeau, Julien Guerin, Enora Laas, Gabriel Benchimol, Anne-Sophie Hamy, Jean-Guillaume Feron, Julie Labrosse, Marick Laé, Jean-Yves Pierga |
| المصدر: | British Journal of Cancer. 124:1421-1427 |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, business.industry, Lymphovascular invasion, Residual cancer, medicine.medical_treatment, Concordance, medicine.disease, 03 medical and health sciences, Global population, 0302 clinical medicine, Breast cancer, 030220 oncology & carcinogenesis, Internal medicine, Female patient, Overall survival, Medicine, business |
| الوصف: | Background To compare RCB (Residual Cancer Burden) and Neo-Bioscore in terms of prognostic performance and see if adding pathological variables improve these scores. Methods We analysed 750 female patients with invasive breast cancer (BC) treated with neoadjuvant chemotherapy (NAC) at Institut Curie between 2002 and 2012. Scores were compared in global population and by BC subtype using Akaike information criterion (AIC), C-Index (concordance index), calibration curves and after adding lymphovascular invasion (LVI) and pre-/post-NAC TILs levels. Results RCB and Neo-Bioscore were significantly associated to disease-free and overall survival in global population and for triple-negative BC. RCB had the lowest AICs in every BC subtype, corresponding to a better prognostic performance. In global population, C-Index values were poor for RCB (0.66; CI [0.61–0.71]) and fair for Neo-Bioscore (0.70; CI [0.65–0.75]). Scores were well calibrated in global population, but RCB yielded better prognostic performances in each BC subtype. Concordance between the two scores was poor. Adding LVI and TILs improved the performance of both scores. Conclusions Although RCB and Neo-Bioscore had similar prognostic performances, RCB showed better performance in BC subtypes, especially in luminal and TNBC. By generating fewer prognostic categories, RCB enables an easier use in everyday clinical practice. |
| تدمد: | 1532-1827 0007-0920 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::46753cc57c119ac8eb570a3cc102a37a https://doi.org/10.1038/s41416-020-01251-3 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi...........46753cc57c119ac8eb570a3cc102a37a |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 15321827 00070920 |
|---|